NLRP3 and experimental autoimmune encephalomyelitis: Other studies have also reported that activating CB2R ameliorates the pathogenesis of experimental autoimmune encephalomyelitis by suppressing the NLRP3 inflammasome [54] and the protective effect of colitis gained via CB2R-mediated inhibition of NLRP3 inflammasome [55].